Front. Physiol. Frontiers in Physiology Front. Physiol. 1664-042X Frontiers Media S.A. 10.3389/fphys.2017.00147 Physiology Correction Corrigendum: Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by Thrombospondin-1 (TSP1): In silico Investigation Bazzazi Hojjat 1 * Isenberg Jeffrey S. 2 Popel Aleksander S. 1 1Department of Biomedical Engineering, School of Medicine, Johns Hopkins University Baltimore, MD, USA 2Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Heart, Lung, Blood, and Vascular Medicine Institute, University of Pittsburgh Pittsburgh, PA, USA

Edited and reviewed by: Shayn Peirce-Cottler, University of Virginia, USA

*Correspondence: Hojjat Bazzazi hbazzazi@jhmi.edu

This article was submitted to Computational Physiology and Medicine, a section of the journal Frontiers in Physiology

 07 03 2017 2017 8 147 09 02 2017 24 02 2017 Copyright © 2017 Bazzazi, Isenberg and Popel. 2017 Bazzazi, Isenberg and Popel

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on Inhibition of VEGFR2 Activation and Its Downstream Signaling to ERK1/2 and Calcium by Thrombospondin-1 (TSP1): In silico Investigation by Bazzazi, H., Isenberg, J. S., and Popel, A. S. (2017). Front. Physiol. 8:48. doi: 10.3389/fphys.2017.00048 TSP1 CD47 VEGF VEGFR2 computational modeling calcium ERK1/2 R01HL101200 (ASP) R01CA138264 (ASP) National Institutes of Health10.13039/100000002

In the original article, there was a mistake in the legend for Figure 3 as published.

“TSP1 inhibition of VEGFR2 signaling with enhanced VEGFR2 degradation. Two nanometer TSP1 is added for 10 min followed by 40 min of 50 ng/ml VEGF…” The correct legend appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

“TSP1 inhibition of VEGFR2 signaling with enhanced VEGFR2 degradation. 2 nM TSP1 is added for 10 min followed by 40 min of 50 ng/ml VEGF…”

Incorrect Author Name

An author name was incorrectly spelled as Jeffery S. Isenberg. The correct spelling is Jeffrey S. Isenberg. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Text Correction

In the original article, there was an error on the Introduction section page 2, paragraph 3:

“…we set out here to interrogate potential mechanisms for the inhibition of VEGF/VEGFR2 signaling to ERK1/2 and calcium by TSP1/CD4 interaction utilizing a detailed rule-based model of VEGF signaling to ERK1/2 and calcium…”

A correction has been made to Introduction, paragraph 3:

“…we set out here to interrogate potential mechanisms for the inhibition of VEGF/VEGFR2 signaling to ERK1/2 and calcium by TSP1/CD47 interaction utilizing a detailed rule-based model of VEGF signaling to ERK1/2 and calcium…”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

In the original article, there was an error on the Conflict of Interest Statement:

“JI serves as chair of the scientific advisory boards of Radiation Control Technologies, Inc. (Jersey City, NJ) and has equity interest in the same and in Tioma Therapeutics (St. Louis, MO).”

A correction has been made to Conflict of Interest Statement:

“JI serves as chair of the scientific advisory board of Radiation Control Technologies, Inc. (Jersey City, NJ) and has equity interest in the same and in Tioma Therapeutics (St. Louis, MO).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Conflict of interest statement

JI serves as chair of the scientific advisory board of Radiation Control Technologies, Inc. (Jersey City, NJ) and has equity interest in the same and in Tioma Therapeutics (St. Louis, MO). The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.